ProCE Banner Activity

Expert Answers to Questions on Pulmonary Arterial Hypertension

Clinical Thought

Read my answers to frequently asked questions on pulmonary arterial hypertension, including epidemiology and classification, diagnostic evaluation, guideline-based management, and emerging therapeutic agents.

Released: October 03, 2024

Expiration: October 02, 2025

Share

Faculty

Vallerie V. McLaughlin

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Faculty Disclosure

Primary Author

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Vallerie V. McLaughlin, MD: researcher: Aerovate, Gossamer Bio, Janssen, Keros, Merck, Sonovie; consultant/advisor/speaker: 35 Pharma, Aerami, Aerovate, CorVista, Gossamer Bio, Janssen, Keros.